Physician profile
Patrick Gotimer
NPI 1316339682
$3,201.09
in general payments reported to CMS, 2019-2025
21 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $835 · 2023: $675 · 2024: $750 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $945.16 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $406.07 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $378.33 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $371.49 | 2021-2024 | Farxiga |
| Impulse Dynamics (USA) INC. | $199.01 | 2025 | Optimizer |
| Pfizer INC. | $179.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $113.78 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $102.84 | 2021-2024 | Xarelto |
| Philips North America LLC | $88.37 | 2023-2025 | (5044) Mcot, Extended Holter |
| Scpharmaceuticals INC. | $63.81 | 2024-2025 | |
| Abbott Laboratories | $61.36 | 2021 | |
| Medtronic, INC. | $58.20 | 2021 | |
| Boston Scientific Corporation | $53.12 | 2022-2023 | |
| Daiichi Sankyo INC. | $49.17 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $29.60 | 2023 | Evkeeza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $23.51 | 2021 | |
| Altathera Pharmaceuticals LLC | $18.08 | 2023 | Sotalol Hydrochloride |
| Irhythm Technologies, INC. | $16.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.45 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.24 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gotimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.